Effectiveness and safety of the hair loss restraint by scalp cooling enforcement addition in the breast cancer chemotherapy

Effectiveness and safety of the hair loss restraint by scalp cooling enforcement addition in the breast cancer chemotherapy - Effectiveness and safety of the hair loss restraint by scalp cooling enforcement addition in the breast cancer chemotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035066

Enrollment

Registered

2018-12-01

Start date

2018-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Scalp cooling is performed, it starts 30 minutes before chemotherapy, and continues until 90 minutes after the end of chemotherapy.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients stage1/2/3 breast cancer

Exclusion criteria

Exclusion criteria: Patients who have malignant blood disease or scalp tumor or cold urticaria.

Design outcomes

Primary

Measure	Time frame
The primary efficacy endpoints are successful hair preservation assessed using the CTCAE4.0scale at the end of 8 cycles of chemotherapy by a clinician unaware of treatment assignment, and device safety.	—

Countries

Japan

Contacts

Public ContactTomoko Kurita

Nippon Medical School Hospital Breast Surgical Oncorogy

tomoko28@nms.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026